{"eventGroups":[{"deathsNumAffected":2,"deathsNumAtRisk":5,"description":"Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells\n\nCarmustine: 300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.\n\nCytarabine: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.\n\nEtoposide: VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells\n\nMelphalan: 140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.\n\nPeripheral Blood Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells","id":"EG000","otherNumAffected":2,"otherNumAtRisk":5,"seriousNumAffected":1,"seriousNumAtRisk":5,"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:0 Ratio"},{"deathsNumAffected":2,"deathsNumAtRisk":4,"description":"Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells","id":"EG001","otherNumAffected":4,"otherNumAtRisk":4,"seriousNumAffected":1,"seriousNumAtRisk":4,"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 1:1 Ratio"},{"deathsNumAffected":1,"deathsNumAtRisk":2,"description":"Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells","id":"EG002","otherNumAffected":0,"otherNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"Treatment (Anti-HIV Gene Transduced CD34+ Cells): 5:1 Ratio"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"BLOOD BILIRUBIN INCREASED"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG001","numAffected":2,"numAtRisk":4,"numEvents":2},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"HYPOALBUMINEMIA"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"HYPOPHOSPHATEMIA"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"LYMPHOCYTE COUNT DECREASED"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":5,"numEvents":2},{"groupId":"EG001","numAffected":2,"numAtRisk":4,"numEvents":2},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"NEUTROPHIL COUNT DECREASED"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5,"numEvents":1},{"groupId":"EG001","numAffected":2,"numAtRisk":4,"numEvents":2},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"PLATELET COUNT DECREASED"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":2},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"WHITE BLOOD CELL DECREASED"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"PLATELET COUNT DECREASED"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"BLOOD BILIRUBIN INCREASED"}],"timeFrame":"24 months after transplant"}